AMRN Jan 2024 4.000 call
| Previous Close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 4.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.0100 - 0.0100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireNew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the Scientific Data and Clinical Use of VASCEPA®/VAZKEPA® to Reduce Cardiovascular Risk -- -- Results Presented Today at the American Heart Association (AHA) Scientific Sessions 2023 and Simultaneously Published in the European Heart Journal Open -- DUBLIN, Ireland
Insider MonkeyAmarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.02. Operator: Welcome to Amarin Corporation’s conference call to discuss its third quarter 2023 financial results and business updates. I would now like to turn the conference call over […]
Simply Wall St.Are Investors Undervaluing Amarin Corporation plc (NASDAQ:AMRN) By 27%?
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Amarin is...
